Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry

Open access
Spithoven, E. M., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Abad, J. M., Areste, N., Alonso de la Torre, R., Caskey, F., Couchoud, C., Finne, P., Heaf, J., Hoitsma, A., de Meester, J., Pascual, J., Postorino, M., Ravani, P., Zurriaga, O., Jager, K. J., Gansevoort, R. T., on behalf of the ERA-EDTA Registry, de los Angeles Garcia Bazaga, M., Metcalfe, W., Rodrigo, E., Quiros, J. R., the EuroCYST Consortium, Budde, K., Devuyst, O., Ecder, T., Eckardt, K. U., Gansevoort, R. T., Kottgen, A., Ong, A. C., Petzold, K., Pirson, Y., Remuzzi, G., Torra, R., Sandford, R. N., Serra, A. L., Tesar, V., Walz, G., the WGIKD, Wuthrich, R. P., Antignac, C., Bindels, R., Chauveau, D., Devuyst, O., Emma, F., Gansevoort, R. T., Maxwell, P. H., Ong, A. C., Remuzzi, G., Ronco, P., Schaefer, F. · 2014 · Nephrology Dialysis Transplantation

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common renal disease requiring renal replacement therapy (RRT). Still, there are few epidemiological data on the prevalence of, and survival on RRT for ADPKD. METHODS: This study used data from the ERA-EDTA Registry on RRT prevalence and survival on RRT in 12 European countries with 208 million inhabitants. We studied four 5-year periods (1991-2010). Survival analysis was performed by the Kaplan-Meier method and by Cox proportional hazards regression. RESULTS: From the first to the last study period, the prevalence of RRT for ADPKD increased from 56.8 to 91.1 per million population (pmp). The percentage of prevalent RRT patients with ADPKD remained fairly stable at 9.8%. Two-year survival of ADPKD patients on RRT (adjusted for age, sex and country) increased significantly from 89.0 to 92.8%, and was higher than for non-ADPKD subjects. Improved survival was noted for all RRT modalities: haemodialysis [adjusted hazard ratio for mortality during the last versus first time period 0.75 (95% confidence interval 0.61-0.91), peritoneal dialysis 0.55 (0.38-0.80) and transplantation 0.52 (0.32-0.74)]. Cardiovascular mortality as a proportion of total mortality on RRT decreased more in ADPKD patients (from 53 to 29%), than in non-ADPKD patients (from 44 to 35%). Of note, the incidence rate of RRT for ADPKD remained relatively stable at 7.6 versus 8.3 pmp from the first to the last study period, which will be discussed in detail in a separate study. CONCLUSIONS: In ADPKD patients on RRT, survival has improved markedly, especially due to a decrease in cardiovascular mortality. This has led to a considerable increase in the number of ADPKD patients being treated with RRT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfu017

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 242

Metadata

Authors
Spithoven, E. M., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Abad, J. M., Areste, N., Alonso de la Torre, R., Caskey, F., Couchoud, C., Finne, P., Heaf, J., Hoitsma, A., de Meester, J., Pascual, J., Postorino, M., Ravani, P., Zurriaga, O., Jager, K. J., Gansevoort, R. T., on behalf of the ERA-EDTA Registry, de los Angeles Garcia Bazaga, M., Metcalfe, W., Rodrigo, E., Quiros, J. R., the EuroCYST Consortium, Budde, K., Devuyst, O., Ecder, T., Eckardt, K. U., Gansevoort, R. T., Kottgen, A., Ong, A. C., Petzold, K., Pirson, Y., Remuzzi, G., Torra, R., Sandford, R. N., Serra, A. L., Tesar, V., Walz, G., WGIKD, T., Wuthrich, R. P., Antignac, C., Bindels, R., Chauveau, D., Devuyst, O., Emma, F., Gansevoort, R. T., Maxwell, P. H., Ong, A. C., Remuzzi, G., Ronco, P., & Schaefer, F.
Venue
Nephrology Dialysis Transplantation
Published
2014-08-27
Volume
29
Issue
suppl 4
Pages
iv15-iv25
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2120488567
Cited by
242
References
1
FWCI
14.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. https://app.cochat.ai/papers/10.1093/ndt/gfu017
The paper
Spithoven, E. M., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Abad, J. M., Areste, N., Alonso de la Torre, R., Caskey, F., Couchoud, C., Finne, P., Heaf, J., Hoitsma, A., de Meester, J., Pascual, J., Postorino, M., Ravani, P., Zurriaga, O., Jager, K. J., . . . Schaefer, F. (2014). Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfu017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.